Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| fibroblast | 7 studies | 26% ± 5% | |
| connective tissue cell | 6 studies | 26% ± 10% | |
| pericyte | 5 studies | 25% ± 6% | |
| smooth muscle cell | 5 studies | 20% ± 6% | |
| myofibroblast cell | 4 studies | 24% ± 7% | |
| adipocyte | 4 studies | 23% ± 7% | |
| epithelial cell of proximal tubule | 3 studies | 24% ± 6% | |
| hepatocyte | 3 studies | 41% ± 14% | |
| endothelial cell | 3 studies | 17% ± 1% |
Insufficient scRNA-seq data for expression of FBXO17 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 4508.14 | 226 / 226 | 96% | 19.23 | 390 / 406 |
| kidney | 100% | 4378.29 | 89 / 89 | 95% | 48.18 | 858 / 901 |
| skin | 100% | 1774.43 | 1808 / 1809 | 86% | 10.99 | 404 / 472 |
| ovary | 100% | 4238.39 | 180 / 180 | 83% | 13.89 | 358 / 430 |
| pancreas | 99% | 804.74 | 326 / 328 | 80% | 5.97 | 142 / 178 |
| uterus | 100% | 3702.35 | 170 / 170 | 69% | 11.26 | 318 / 459 |
| prostate | 100% | 2457.30 | 245 / 245 | 61% | 4.12 | 306 / 502 |
| breast | 100% | 2117.67 | 459 / 459 | 60% | 4.73 | 671 / 1118 |
| lung | 100% | 1310.47 | 577 / 578 | 58% | 6.34 | 674 / 1155 |
| adrenal gland | 86% | 536.36 | 221 / 258 | 69% | 6.70 | 159 / 230 |
| esophagus | 99% | 1620.94 | 1433 / 1445 | 55% | 5.04 | 100 / 183 |
| brain | 96% | 1221.23 | 2528 / 2642 | 44% | 6.97 | 311 / 705 |
| bladder | 100% | 2297.76 | 21 / 21 | 35% | 3.20 | 178 / 504 |
| stomach | 90% | 1022.30 | 324 / 359 | 35% | 2.72 | 100 / 286 |
| intestine | 90% | 1534.84 | 871 / 966 | 21% | 1.70 | 113 / 527 |
| thymus | 94% | 728.93 | 615 / 653 | 6% | 0.43 | 36 / 605 |
| adipose | 100% | 2470.77 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2329.82 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 8.80 | 1 / 1 |
| spleen | 78% | 481.38 | 188 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 71% | 5.54 | 32 / 45 |
| heart | 69% | 655.62 | 592 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 61% | 7.42 | 49 / 80 |
| muscle | 18% | 90.11 | 147 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 7% | 52.48 | 62 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.14 | 1 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
| GO_0036503 | Biological process | ERAD pathway |
| GO_0006516 | Biological process | glycoprotein catabolic process |
| GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FBXO17 |
| Protein name | F-box only protein 17 (F-box only protein 26) F-box protein 17 Alternative protein FBXO17 |
| Synonyms | FBX17 FBX26 FBXO26 FBG4 |
| Description | FUNCTION: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Able to recognize and bind denatured glycoproteins, which are modified with complex-type oligosaccharides. Also recognizes sulfated glycans. Does not bind high-mannose glycoproteins. |
| Accessions | ENST00000292852.9 L8E8U1 Q96EF6 M0QYV7 ENST00000596025.5 ENST00000595329.5 M0QZ95 ENST00000599598.1 ENST00000601394.1 ENST00000634982.2 M0QYI3 ENST00000635115.1 |
